VIDEO: Assessment tool rapidly screens lupus cognition

ROME – The Montreal Cognitive Assessment provides a quick and easy-to-use screening tool to identify patients with systemic lupus erythematosus with cognitive impairment, Dr. Zahi Touma reported in a poster at the European Congress of Rheumatology.

In a consecutive series of 78 patients screened with the Montreal Cognitive Assessment (MoCA), the free, single-page test, which can be administered in about 10 minutes, showed a sensitivity of 69% and specificity of 68%, compared with the current standard, the Hopkins Verbal Learning Test-Revised, said Dr. Touma, a rheumatologist at the University of Toronto.

Other easy-to-use and quick screening tools, such as the Mini-Mental State Examination, had substantially worse performance in the study. He and his associates found a sensitivity of 21% and specificity of 91% using the Mini-Mental State exam. For screening, higher sensitivity is desirable so that fewer patients with potential cognitive impairment are missed, he noted.

“Ease of use and time needed for assessment as well as appropriate psychometric properties make the MoCA the preferential screening test for cognitive impairment in patients with SLE,” Dr. Touma said in his poster.

Cognitive impairment is very common among patients with systemic lupus erythematosus (SLE). In this study, Dr Touma found a 47% prevalence using MoCA. Cognitive impairment, however, often goes unidentified in SLE patients, likely because of lack of awareness among rheumatologists as well as the absence of a quick and easily administered screening tool, he said in a video interview.

Dr. Touma said he hopes that the apparent efficacy of an easy-to-use screening tool like MoCA will help boost appreciation for the high prevalence of cognitive impairment in SLE patients. He suggested that clinicians screen for cognitive impairment as soon as SLE is diagnosed and that they perform follow-up screening during subsequent patient encounters with SLE patients who initially present without cognitive impairment.

Dr. Touma had no disclosures.

[email protected]

On Twitter @mitchelzoler

ROME – The Montreal Cognitive Assessment provides a quick and easy-to-use screening tool to identify patients with systemic lupus erythematosus with cognitive impairment, Dr. Zahi Touma reported in a poster at the European Congress of Rheumatology.

In a consecutive series of 78 patients screened with the Montreal Cognitive Assessment (MoCA), the free, single-page test, which can be administered in about 10 minutes, showed a sensitivity of 69% and specificity of 68%, compared with the current standard, the Hopkins Verbal Learning Test-Revised, said Dr. Touma, a rheumatologist at the University of Toronto.

Other easy-to-use and quick screening tools, such as the Mini-Mental State Examination, had substantially worse performance in the study. He and his associates found a sensitivity of 21% and specificity of 91% using the Mini-Mental State exam. For screening, higher sensitivity is desirable so that fewer patients with potential cognitive impairment are missed, he noted.

“Ease of use and time needed for assessment as well as appropriate psychometric properties make the MoCA the preferential screening test for cognitive impairment in patients with SLE,” Dr. Touma said in his poster.

Cognitive impairment is very common among patients with systemic lupus erythematosus (SLE). In this study, Dr Touma found a 47% prevalence using MoCA. Cognitive impairment, however, often goes unidentified in SLE patients, likely because of lack of awareness among rheumatologists as well as the absence of a quick and easily administered screening tool, he said in a video interview.

Dr. Touma said he hopes that the apparent efficacy of an easy-to-use screening tool like MoCA will help boost appreciation for the high prevalence of cognitive impairment in SLE patients. He suggested that clinicians screen for cognitive impairment as soon as SLE is diagnosed and that they perform follow-up screening during subsequent patient encounters with SLE patients who initially present without cognitive impairment.

Dr. Touma had no disclosures.

[email protected]

On Twitter @mitchelzoler

ROME – The Montreal Cognitive Assessment provides a quick and easy-to-use screening tool to identify patients with systemic lupus erythematosus with cognitive impairment, Dr. Zahi Touma reported in a poster at the European Congress of Rheumatology.

In a consecutive series of 78 patients screened with the Montreal Cognitive Assessment (MoCA), the free, single-page test, which can be administered in about 10 minutes, showed a sensitivity of 69% and specificity of 68%, compared with the current standard, the Hopkins Verbal Learning Test-Revised, said Dr. Touma, a rheumatologist at the University of Toronto.

Other easy-to-use and quick screening tools, such as the Mini-Mental State Examination, had substantially worse performance in the study. He and his associates found a sensitivity of 21% and specificity of 91% using the Mini-Mental State exam. For screening, higher sensitivity is desirable so that fewer patients with potential cognitive impairment are missed, he noted.

“Ease of use and time needed for assessment as well as appropriate psychometric properties make the MoCA the preferential screening test for cognitive impairment in patients with SLE,” Dr. Touma said in his poster.

Cognitive impairment is very common among patients with systemic lupus erythematosus (SLE). In this study, Dr Touma found a 47% prevalence using MoCA. Cognitive impairment, however, often goes unidentified in SLE patients, likely because of lack of awareness among rheumatologists as well as the absence of a quick and easily administered screening tool, he said in a video interview.

Dr. Touma said he hopes that the apparent efficacy of an easy-to-use screening tool like MoCA will help boost appreciation for the high prevalence of cognitive impairment in SLE patients. He suggested that clinicians screen for cognitive impairment as soon as SLE is diagnosed and that they perform follow-up screening during subsequent patient encounters with SLE patients who initially present without cognitive impairment.

Dr. Touma had no disclosures.

[email protected]

On Twitter @mitchelzoler